A low moisture sugarless syrup for use in chewing gums, methods of making the syrup, chewing gums using the syrup, and methods for making such chewing gums are disclosed. The syrups comprise from about 10% to about 40% of a plasticizer selected from the group consisting of glycerin, propylene glycol and mixtures thereof; from about 40% to about 85% alditols with at least 60% of the alditols (by weight of the alditols) consisting of maltitol; and from about 5% to about 35% water.

Low moisture sugarless syrups with maltitol for chewing gum

A syrup containing N-acetyl-cysteine, stable for at least two years, having pleasant taste and smell, consists of an aqueous solution of NAC, a sweetening agent and a thickening agent The solution can also contain a flavoring agent and a preservative The pH is between 5 and 8

Syrup containing N-acetyl-cysteine

On prepare un principe actif habituellement presente sous forme de sirop en flacon, dans un excipient sous forme de gel pseudoplastique que l'on conditionne en emballage distributeur avec pompe doseuse, de maniere que la dose therapeutique soit delivree en une ou deux pressions sur la pompe par prise therapeutique. Preparing an active ingredient usually in the form of syrup bottle, in an excipient as pseudoplastic gel as in the dispenser package is packaged with dosing pump, such that the therapeutic dose to be delivered in one or two presses of the pump by therapeutic outlet. Ce mode de presentation apporte la precision de dosage, la facilite, l'hygiene et la securite d'utilisation en particulier chez les bebes, nourrissons, jeunes enfants et geriatres. This presentation mode brings the dosing accuracy, ease, hygiene and in particular the safe use in babies, infants, young children and geriatricians.

Gel composition in a dispenser

An NK1 receptor antagonist composition of the present invention uses maltooligosaccharide having an NK1 receptor antagonistic activity as an active ingredient. A suitable amount of the maltooligosaccharide to be blended in the NK1 receptor antagonist composition of the present invention is 0.000001 to 70% by weight. The NK1 receptor antagonist composition of the present invention is prepared for use into various forms of external agents, internal medicines, foods and beverages by blending various materials as the ingredients other than the active ingredient. The NK1 receptor antagonist composition of the present invention has high safety for being used for pharmaceuticals and has satisfactory therapeutic effects.

Nk1 receptor antagonist composition

Sirop contenant de la N-acetyl-cysteine, stable pendant au moins 2 ans, ayant une odeur et un gout plaisants, constitue d'une solution aqueuse de NAC, d'un agent edulcorant et d'un agent epaississant, la solution pouvant egalement contenir un agent aromatisant et un agent de conservation, le pH se situant entre 5 et 8.

Sirop contenant de la n-acetyl-cysteine.

The invention relates to the use of a pentitol, chosen from xylitol, ribitol or adonitol, and arabitol, both in the racemic form and in the form of one of its optically active isomers, in the preparation of non-cariogenic syrups for the oral administration of therapeutically active principles having a symptomatic action, the aforementioned active principle being chosen from those of antitussive, anti-inflammatory, analgesic and antipyretic medicaments.

Enzo Moroni

Papers

Syrups based on xylitol, ribitol or arabitol